Garden State Investment Advisory Services’s Orchestra BioMed OBIO Stock Holding History

Garden State Investment Advisory Services’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44.9K	Buy	+10,562	New	+$45K	0.01%	330

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Garden State Investment Advisory Services's OBIO Position: Q1 2026 in Review

Garden State Investment Advisory Services opened a new position in Orchestra BioMed (OBIO) in Q1 2026: 10,562 shares worth $44.9K. The stake represents 0.01% of the portfolio and ranks #330 among its holdings.

65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

Garden State Investment Advisory Services held 10,562 shares of Orchestra BioMed worth $44.9K as of Q1 2026.
Orchestra BioMed was a new Garden State Investment Advisory Services position in Q1 2026.
Orchestra BioMed made up 0.01% of Garden State Investment Advisory Services's portfolio in Q1 2026, its #330 holding.
65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Garden State Investment Advisory Services's 13F filing for Q1 2026, filed 14 May 2026.